Recommendations:

• •

  Studies of the susceptibility of uropathogens in the community tend to overestimate resistance rates. To guide empiric treatment, susceptibility and clinical data (type of UTI (uncomplicated versus complicated), sex, age and previous antibiotic therapy should be considered (A-II)).

• •

  An antimicrobial agent is not recommended for empiric treatment of urinary tract infections if local resistance prevalence is over 20% for cystitis (B-II) or 10% for pyelonephritis (C-III).

Recommendations:

• •

  In women with uncomplicated cystitis, empiric treatment should be initiated on the basis of symptoms alone. A urine culture is generally not necessary (E-I).

• •

  A pre-treatment urine culture should be obtained when the diagnosis is not clear from the history and physical examination, when the episode represents an early symptomatic recurrence, when there is reason to suspect antimicrobial resistance or the patient's therapeutic options are limited due to medication intolerance (A-II).

• •

  Routine post-treatment cultures are not indicated for asymptomatic women following treatment for cystitis (E-II) and should only be obtained if symptoms persist or recur soon after treatment (A-II).

Recommendations:

• •

  The available evidence suggests that there is no need to routinely take a blood culture from women with uncomplicated pyelonephritis (E-II). It seems reasonable, however, to obtain a blood culture from patients with complicated infections, those receiving antibiotics or who have severe sepsis (B-II).

Recommendations:

• •

  Urine samples for culture should be collected in a manner that minimizes contamination (A-II).

• •

  For symptomatic women, a culture definition for cystitis is ≥102CFU/mL (A-I) of a uropathogen, and for pyelonephritis ≥104CFU/mL (A-II). In non-catheter-related cystitis, counts of ≥102CFU/mL are significant in urine samples obtained by catheterization (B-III).

• •

  In males with cystitis, a culture of ≥103CFU/mL is considered to be significant (A-III).

• •

  In women with cystitis, the concomitant isolation of enterococci or group B streptococci with an enterobacteriaceae in a midstream urine culture has low clinical significance (A-I).

• •

  In patients with indwelling urethral, indwelling suprapubic, or intermittent catheterization, symptomatic UTI is microbiologically defined as the presence of ≥103CFU/mL of a bacterial species in a single catheter urine specimen or a midstream voided urine specimen from a patient whose urethral, suprapubic, or condom catheter has been removed within the previous 48h (A-III).

• •

  In bladder urine obtained by suprapubic aspiration, any number of bacteria is considered to be significant (A-II).

• •

  In women with asymptomatic bacteriuria, two consecutive clean-voided specimens with the same uropathogen at counts of ≥105CFU/mL, or one positive urine culture with a positive nitrite test in another sample, are required for diagnosis (B-II). In men, bacteriuria is defined as a single uropathogen isolated at a count of ≥105CFU/mL (B-III).

• •

  Asymptomatic bacteriuria in patients with indwelling urethral, indwelling suprapubic, or intermittent catheterization is microbiologically defined as the presence of ≥105CFU/mL of a bacterial species in a single catheter urine specimen or a midstream voided urine specimen from a patient whose urethral (A-III), suprapubic (A-III), or condom catheter (A-II) has been removed within the previous 48h.

Recommendations:

• •

  Bacterial killing is best described by indices incorporating the antimicrobial's PK and PD parameters and the minimum inhibitory concentration (MIC), the lowest concentration of the antimicrobial required to prevent the growth of the target organism (B-II).

Recommendations:

• •

  Specific susceptibility breakpoints for UTI isolates are recommended (B-III). EUCAST and CLSI have published several breakpoints that are valid only for isolates in uncomplicated urinary tract infections.

Recommendations:

• •

  Human data indicates that urinary concentrations are more closely associated with clinical outcomes than serum concentrations for lower UTI. For the treatment of pyelonephritis, however, high serum concentrations of the antimicrobial agent are required (A-III).

• •

  With beta-lactams, the efficacy of sequential therapy may decrease due to the significant reduction in exposure to the active drug when switching to oral formulations for pathogens with higher MIC values (C-III).

Recommendations:

• •

  Pyuria cannot be considered as an adequate criterion for the diagnosis of AB nor for indication for treatment in a patient with AB (A-II). Urine test stripes are not recommended for the detection of AB (A-II).

Recommendations:

• •

  Systematic screening and treatment of AB is recommended for pregnant women (A-I) in order to reduce the risk of pyelonephritis (A-I), preterm labour and low birth weight infants (B-II). An initial urine culture between the 12th and 16th weeks of pregnancy is recommended (A-I).

• •

  A follow-up urine culture is recommended in order to verify that the bacteriuria has been eradicated (A-III). Subsequent monthly urine cultures until delivery are recommended (C-III).

Recommendations:

• •

  Systematic screening for and treatment of AB is recommended prior to performing a TURP of the prostate (A-I) or any other high-risk urological procedure (A-II).

• •

  Screening and prophylaxis for AB is not recommended for patients scheduled to undergo low-risk urological procedures (A-I).

• •

  Antibiotic prophylaxis should be initiated immediately before performing the procedure (A-II) and may be prolonged only in patients with a short-term urethral catheter, until removal (C-III).

Recommendations:

• •

  Systematic screening for AB is not recommended for non-pregnant women under the age of 60 (E-I).

• •

  Treatment of AB in non-pregnant women under the age of 60 increases the risk of sUTI and rates of antibiotic resistance (B-I).

Recommendation:

• •

  Systematic screening for and treatment of AB is not recommended for non-pregnant diabetic women (E-I).

Recommendations:

• •

  Systematic screening for and treatment of AB is not recommended for patients with short-term (E-II) or long-term urinary catheters (E-I).

• •

  Treatment of AB in women is recommended only if AB persists 48h after removal of the catheter (B-I).

• •

  Systemic antibiotic prophylaxis is not recommended during catheter replacement, since the risk of onset of symptomatic bacteremia is low (E-II); nonetheless, it may be recommended in cases of traumatic replacement associated with hematuria (C-III).

Recommendation:

• •

  Systematic screening and/or treatment of AB is not recommended for elderly patients living in the community (E-II).

Recommendation:

• •

  Systematic screening and/or treatment of AB is not recommended for institutionalised elderly patients (E-I).

Recommendations:

• •

  Systematic diagnosis or treatment of AB is not recommended for patients scheduled to undergo total hip or knee arthroplasty (A-I).

• •

  Screening and treatment of AB prior to performing instrumental spinal surgery is recommended for patients with urinary catheters, neurogenic bladders or urinary incontinence in order to reduce the risk of Gram-negative surgical site infections (B-II).

Recommendation:

• •

  Systematic screening and treatment of AB is not recommended for patients with spinal cord injury treated with intermittent urinary catheterization (E-II).

Recommendations:

• •

  For kidney transplant patients, the screening and treatment of AB is only recommended in the first month after transplantation (B-III).

• •

  For cases of hematopoietic stem cell transplants and SOTs other than kidney transplants, no recommendations for the screening and treatment of AB can be made (C-III).

• •

  Systemic antifungal therapy for asymptomatic candiduria is not recommended for transplant patients, except for neutropenic patients or those scheduled to undergo urological procedures (D-III).

Recommendation:

• •

  Systematic screening and treatment of AB is not recommended in patients with an orthotopic neobladder (D-III).

Recommendation:

• •

  Standard 4- to 7-day treatment regimens are better than short one-day treatments for eradicating bacteriuria (A-I). Only a single 3g dose of FT offers similar results to the standard treatment regimen (A-I).

Recommendations:

• •

  Due to minimal resistance and propensity for collateral damage, fosfomycin-trometamol (3g in a single dose) and nitrofurantoin (for 5–7 days) are considered the first-choice drugs for therapy of uncomplicated cystitis (A-I).

• •

  Fluoroquinolones (ciprofloxacin, levofloxacin and norfloxacin) are highly efficacious in 3-day regimens (A-I), but should be considered as alternative antimicrobials because of their high propensity for collateral damage (B-III).

• •

  β-Lactam agents, including amoxicillin-clavulanate, cefuroxime, ceftibuten, for 5 days, and cefixime for 3 day regimens, are appropriate choices for therapy when other recommended agents cannot be used (B-I). β-Lactams generally have inferior efficacy and more adverse effects when compared with other UTI antimicrobials (B-I). Ampicillin and amoxicillin should not be used for the empiric treatment of uncomplicated cystitis, given the high incidence of antimicrobial resistance to these agents (E-I).

• •

  Co-trimoxazole is not recommended for empiric treatment in Spain, because the resistance rate in E. coli is greater than 20% (E-I). If the infectious organism is susceptible to co-trimoxazole, this agent is very effective therapy (A-I).

• •

  In men, and in women with symptoms longer than 7 days, recent UTI, diabetes, renal insufficiency, immunosuppression or with a vaginal diaphragm a longer course of antibiotic therapy (at least 7 days) is recommended (C-III).

Recommendations:

• •

  Women with uncomplicated APN and mild to moderate symptoms (fever <39°C, no severe flank pain, no vomiting) can be treated as outpatients (A-II).

• •

  Women with uncomplicated APN but with social, mental or physical disabilities that might hinder adherence to a prescribed therapeutic regimen should be admitted to hospital (C-III).

• •

  Women with uncomplicated APN and severe symptoms (fever ≥39°C, severe flank pain, vomiting) should be referred to an emergency room for evaluation, parenteral antibiotics and supportive measures (A-II). If, after 24h, there is improvement and good oral tolerance, the patient may be sent home with oral antibiotics (A-II).

• •

  Patients with complicated APN or healthcare-associated APN and those with risk factors for MDR Enterobacteriaceae should be admitted to hospital (A-II).

• •

  Pregnant women with otherwise uncomplicated APN and non-severe symptoms may be considered for treatment as outpatients if appropriate follow-up is assured (B-I). A normal abdominal ultrasonography is recommended before discharge (C-III).

• •

  Selected APN patients with no severe sepsis, no obstructive uropathy (as recorded by ultrasonography), no altered mental status, no metabolic abnormalities and who have a responsible caregiver at home, may be managed in a hospital-based home care unit (B-III).

Recommendations:

• •

  In our setting, ampicillin, amoxicillin, amoxicillin-clavulanic acid, co-trimoxazole, fluoroquinolones, nitrofurantoin and fosfomycin-tromethamine are not recommended for the empiric treatment of acute pyelonephritis (A-III).

• •

  Parenteral antibiotic treatment is recommended as initial therapy for patients requiring hospital admission (A-III).

• •

  In patients with uncomplicated community-acquired acute pyelonephritis with no specific risk factors for ESBL-producing Enterobacteriaceae, empiric therapy with cefuroxime or a third-generation cephalosporin is recommended (A-II). For allergic patients, the alternatives are an aminoglycoside (B-I), aztreonam (B-II) or fosfomycin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).

• •

  In community-acquired APN with specific risk factors for ESBL-producing Enterobacteriaceae (at least two risk factors without severe sepsis and one with it) or previous infection/colonization with ESBL, ertapenem is an acceptable option (C-II), although other carbapenems (B-II) or piperacillin-tazobactam (B-III) are alternatives. For patients with penicillin allergy, the alternatives are amikacin (B-I) or intravenous sodium fosfomycin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).

• •

  In healthcare-associated APN, an antipseudomonal carbapenem is recommended (A-III) with ceftolozane-tazobactam or piperacillin-tazobactam as alternatives (C-III). For patients with severe sepsis, the addition of amikacin should be considered in order to increase the chances of providing appropriate empiric therapy against Gram-negative bacilli (B-II). For patients allergic to penicillin, alternative treatments are aztreonam, amikacin or intravenous sodium fosfomycin±amikacin (C-III); a carbapenem is an acceptable option if the patient is closely monitored (C-III).

• •

  Anti-enterococcal coverage is recommended for patients with healthcare-related APN and severe sepsis or cardiac conditions at high risk of endocarditis (C-III).

• •

  When the antibiotic susceptibility pattern is known, treatment should preferably be adjusted to the drug with least ecological impact, such as co-trimoxazole (C-III).

Recommendations:

• •

  In patients with uncomplicated acute pyelonephritis due to susceptible Gram-negative enteric bacilli, 5–7 days of levofloxacin or ciprofloxacin is recommended (A-I).

• •

  In the case of third-generation oral or parenteral cephalosporins, a 7 to 10-day course is recommended (A-I). For amoxicillin-clavulanic acid and co-trimoxazole a 10-day course is recommended (A-III). For aminoglycosides, no more than a 5-day course is recommended (A-II).

• •

  For patients with severe or focal APN or slow response to appropriate antibiotics, a longer duration of therapy may be required (C-III).

Recommendations:

• •

  Urological studies are only recommended for patients with uncomplicated APN who continue with fever after 3 days of appropriate antibiotic treatment (A-III), for APN that fulfils the definition of complicated infection in these guidelines (including severe sepsis) (A-III) or for recurrent APN (C-III).

• •

  Urological study should also be considered when the clinical diagnosis is doubtful, either to confirm it or to rule out other processes (C-III).

Recommendations:

• •

  In patients with short-term catheterization, UTI is usually monomicrobial and frequently caused by Enterobacteriaceae (B-II).

• •

  In patients with long-term catheterization, UTI is usually polymicrobial and frequently caused by antimicrobial-resistant bacteria (B-II).

Recommendations:

• •

  If an indwelling catheter has been in place for >2 weeks, the catheter should be replaced before obtaining urine for culture (A-II).

• •

  Signs and symptoms compatible with CA-UTI include fever, rigors, altered mental state or malaise with no other identifiable cause, as well as focal signs in the urinary tract, such as flank or pelvic pain, costovertebral angle tenderness, and acute hematuria (A-III).

• •

  In catheterised patients, the presence of urinary symptoms is of limited value for differentiating CA-AB from CA-UTI (A-I). In patients whose catheters have been removed, the presence of urinary symptoms is suggestive of symptomatic UTI (A-III).

• •

  In patients with spinal cord injuries, increased spasticity, autonomic dysreflexia, or a sense of unease are suggestive of CA-UTI (A-III).

• •

  In patients with indwelling catheters residing in LTCFs, the clinical criteria for obtaining urine cultures and initiating antimicrobial therapy include fever, costovertebral angle tenderness, rigors or new onset delirium with no other obvious source (A-II).

• •

  In catheterised patients, the presence or absence of odorous or cloudy urine should not be used to distinguish CA-AB from CA-UTI or as an indication for a urine culture or antimicrobial therapy (A-III).

Recommendations:

• •

  In catheterised patients, pyuria is not diagnostic of CA-AB or CA-UTI (A-II). The absence of pyuria in a symptomatic patient suggests a diagnosis other than CA-UTI (A-III).

Recommendation:

• •

  In catheterised patients, the urine Gram stain may be useful for guiding empiric antibiotic therapy in patients with severe UTI (B-III).

Recommendation:

• •

  In catheterised patients with suspected UTI, recent use of beta-lactams or quinolones should be investigated in order to evaluate the risk for MDR bacteria (B-II).

Recommendations:

• •

  Antimicrobial therapy is indicated for patients with symptomatic infection or clinical signs of sepsis (B-III).

• •

  Patients with symptomatic UTI and criteria for severe sepsis should be treated with parenteral broad-spectrum antibiotics adapted to the local resistance patterns of uropathogens (C-III). Imipenem, meropenem and piperacillin/tazobactam are the most active antimicrobials in our setting. If the patient has septic shock or resistance to beta-lactams is suspected, combination therapy with amikacin should be considered (C-III).

• •

  If the patient presents with symptoms of mild infection and a urinary origin is unlikely, antimicrobial therapy can be delayed until the urine culture results are known (C-III).

Recommendations:

• •

  Seven days is the usual duration of antimicrobial therapy for CA-UTI patients with prompt resolution of symptoms, and patients with cystitis following urinary catheterization (A-III); 10–14 days of treatment is recommended for those with delayed response (A-III), regardless of whether the patient remains catheterised or not.

• •

  A 5-day course of levofloxacin may be considered for patients with mild CA-UTI (B-III). A 3-day course of antimicrobials (B-II) or a single-dose of fosfomycin trometamol (3g) (C-III) may be considered for women who develop CA-UTI without upper urinary tract symptoms after removal of an indwelling catheter.

• •

  Antibiotic prophylaxis should not be administered to patients for catheter placement (E-I) catheter removal (D-I) or replacement (E-III) in order to prevent CA-UTI.

Recommendations:

• •

  Indwelling catheters should be placed only when they indicated (A-III) and should be removed as soon as they are no longer required, in order to reduce the risk of CA-AB (A-I) and CA-UTI (A-II). Indwelling catheters should be inserted using the aseptic technique and sterile equipment (B-III) and a closed catheter drainage system should be maintained to reduce CA-AB and CA-UTI (A-II and A-III, respectively, for patients with short-term catheters; A-III and A-III, respectively, for patients with long-term catheters).

• •

  Appropriate alternatives to short- and long-term urethral catheterization should be considered for reducing CA-AB, such as condom catheterization (A-II and B-II, respectively) intermittent catheterization (C-I and A-III, respectively), and suprapubic catheterization (B-I for short-term catheterization). Alternatives for reducing CA-UTI are intermittent catheterization (C-III for short-term and A-III for long-term catheterization) and suprapubic catheterization (C-III for short-term catheterization).

• •

  In patients with short-term indwelling urethral catheterization, antimicrobial (antibiotic or silver alloy)-coated urinary catheters may reduce or delay the onset of CA-AB, but does not decrease the frequency of CA-UTI (B-II).

• •

  Systemic antibiotic prophylaxis should not be routinely used to reduce CA-AB or CA-UTI in patients with short-term (A-III) or long-term (A-II) catheterization because of the concern of selection of antimicrobial resistance.

Recommendations:

• •

  In sexually active women, the main risk factor for rUTI is frequency of sexual intercourse (B-I).

• •

  In sexually active women with rUTI, it is not necessary to perform a urological study if there is no suspicion of underlying urological disease (A-II).

Recommendation:

• •

  In women who fail to prevent rUTI with hygiene measures, it is not necessary to insist on their implementation (B-II).

Recommendations:

• •

  Vitamin C (ascorbic acid) in acceptable dosing intervals in regular clinical practice is not useful in the prevention of rUTI (B-II).

• •

  Although methenamine hippurate is useful for preventing rUTI (B-I), we do not recommend its use, given the potential carcinogenic risks (C-III).

Recommendations:

• •

  In women with fewer than 3 UTIs per year, self-treatment of cystitis is a convenient and effective measure and also reduces the consumption of antibiotics associated with prophylaxis (B-II).

• •

  The administration of continuous (A-I) or post-coital (A-I) antibiotics, topical vaginal estrogens (A-I), cranberries (A-II) or D-Mannose (A-II) for a 6-month period reduces the frequency of rUTI to a greater or lesser extent.

Recommendations:

• •

  In women with rUTI, continuous or postcoital antibiotic prophylaxis administered for 6–12 months is highly effective for reducing recurrence (A-I).

• •

  The effectiveness of the different antibiotics used in prophylaxis (COT, NIT, trimethoprim, FQs and cephalosporins) is similar (B-II).

• •

  If UTI recurs after cessation of prophylaxis, it is recommended to restart the same prophylaxis regimen for a longer period (1–2 years) (C-III).

• •

  Due to its ecological impact, prophylaxis with FQs should be used only when no other preventive strategy is available (C-III).

Recommendations:

• •

  Cranberries administered for 6–12 months are moderately effective in preventing new episodes of UTI in patients with rUTI (A-I); in patients with few UTIs, they are not effective (A-II).

• •

  Antibiotic prophylaxis is more effective than cranberries (A-I).

• •

  A 72mg dose, or higher, of PAC is recommended (C-III).

Recommendations:

• •

  In menopausal women without neurological diseases, the main risk factors for suffering rUTI are urinary incontinence, previous gynaecological surgery, presence of diabetes mellitus, a cystocele, residual urine and a history of rUTI before menopause (B-II).

• •

  The role of sexual activity is less relevant as a predisposing factor for recurrence in postmenopausal women (B-II).

Recommendations:

• •

  Oral administration of estrogen does not reduce rUTI (E-I).

• •

  Vaginal estrogen significantly reduces rUTI (A-II).

• •

  It is not known whether antibiotic prophylaxis is more efficacious than vaginal creams (C-II).

• •

  Vaginal estrogen administration is the prophylaxis of choice when associated with vaginal atrophy and should always be considered in all postmenopausal patients (C-III).

Recommendations:

• •

  Oral and intranasal vaccines (OM-89) made from uropathogenic bacterial extracts are moderately effective in preventing rUTI (B-II).

• •

  There are no adequate studies assessing the effectiveness of other commercialised preparations (C-III).

Recommendations:

• •

  There is insufficient evidence to recommend vaginal application of lactobacilli as a strategy for preventing rUTI (B-II).

• •

  D-mannose is effective in preventing rUTI (A-II). Its effectiveness is similar to nitrofurantoin for this indication (A-II).